Proflavin suppresses the growth of human osteosarcoma MG63 cells through apoptosis and autophagy

Zhang,Mao‑Shu; Niu,Fu‑Wen; Li,Kun

doi:10.3892/ol.2015.3206

Proflavin suppresses the growth of human osteosarcoma MG63 cells through apoptosis and autophagy

Authors:
- Mao‑Shu Zhang
- Fu‑Wen Niu
- Kun Li
View Affiliations

Affiliations: Department of Orthopaedics, Jining No. 1 People's Hospital, Jining, Shandong 272011, P.R. China, Department of Gynaecology and Obstetrics, Affiliated Hospital of Shandong Academy of Medical Sciences, Jinan, Shandong 250062, P.R. China
Published online on: May 14, 2015 https://doi.org/10.3892/ol.2015.3206
Pages: 463-468

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Proflavin is one of the novel acridine derivatives that possess various pharmacological effects. Although numerous studies have been performed to investigate proflavin, its effects have not been investigated on the human osteosarcoma MG63 cell line. The core aim of the present study was to test the effects of proflavin on the viability of MG63 cells and the induction of apoptosis and autophagy in MG63 cells. The induction of apoptosis was examined by measuring the changes in the expression of the B‑cell lymphoma 2 (Bcl‑2) and Bcl‑2‑associated X protein mRNA and proteins. Apoptotic cell death was identified by the proteolytic cleavage of poly (adenosine diphosphate‑ribose) polymerase and caspase‑3 and caspase‑9. In addition, the autophagic effects of proflavin were examined by the quantitation of the mRNA expression of autophagy protein 5 and Beclin 1, in addition to the identification of the accumulation of microtubule‑associated protein 1 light chain 3‑II. The present results revealed that proflavin inhibited the proliferation of MG63 cells in a dose‑dependent manner. Proflavin‑induced cell death was attributed to apoptosis and autophagy. Overall, the present results indicated that the antiseptic agent proflavin exerts anticancer potential through the synergistic activity of apoptosis and autophagy.

View Figures

View References

1	Kaatsch P: Epidemiology of childhood cancer. Cancer Treat Rev. 36:277–285. 2010. View Article : Google Scholar : PubMed/NCBI
2	Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, Kotz R, Salzer-Kuntschik M, Werner M, Winkelmann W, et al: Prognostic factors in high-grade osteosarcoma of the extremities or trunk: An analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 20:776–790. 2002. View Article : Google Scholar : PubMed/NCBI
3	Longhi A, Errani C, De Paolis M, Mercuri M and Bacci G: Primary bone osteosarcoma in the pediatric age: State of the art. Cancer Treat Rev. 32:423–436. 2006. View Article : Google Scholar : PubMed/NCBI
4	Lee JA, Kim MS, Kim DH, Lim JS, Yoo JY, Koh JS, Lee SY, Jeon DG and Park KD: Relative tumor burden predticts metastasis-free survival in pediatric osteosarcoma. Pediatr Blood Cancer. 50:195–200. 2008. View Article : Google Scholar : PubMed/NCBI
5	Bacci G, Longhi A, Versari M, Mercuri M, Briccoli A and Picci A: Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer. 106:1154–1161. 2006. View Article : Google Scholar : PubMed/NCBI
6	O'Driscoll L: Mechanisms of drug sensitivity and resistance in cancer. Curr Cancer Drug Targets. 9:250–251. 2009. View Article : Google Scholar : PubMed/NCBI
7	Anninga JK, Gelderblom H, Fiocco M, Kroep JR, Taminiau AH, Hogendoorn PC and Egeler AM: Chemotherapeutic adjuvant treatment for osteosarcoma: Where do we stand? Eur J Cancer. 47:2431–2445. 2011. View Article : Google Scholar : PubMed/NCBI
8	Luetke A, Meyers PA, Lewis I and Juergens H: Osteosarcoma treatment - where do we stand? A state of the art review. Cancer Treat Rev. 40:523–532. 2014. View Article : Google Scholar : PubMed/NCBI
9	McTiernan A, Jinks RC, Sydes MR, Uscinska B, Hook JM, van Glabbeke M, Bramwell V, Lewis IJ, Taminiau AH, Nooij MA, et al: Presence of chemotherapy-induced toxicity predicts improved survival in patients with localised extremity osteosarcoma treated with doxorubicin and cisplatin: A report from the European osteosarcoma intergroup. Eur J Cancer. 48:703–712. 2012. View Article : Google Scholar : PubMed/NCBI
10	Janeway KA and Grier HE: Sequelae of osteosarcoma medical therapy: A review of rare acute toxicities and late effects. Lancet Oncol. 11:670–678. 2010. View Article : Google Scholar : PubMed/NCBI
11	Acheson RM: Acridines. Interscience Publishers; New York, NY: pp. 10–90. 1973
12	Li HJ and Crothers DM: Relaxation studies of the proflavine-DNA complex: The kinetics of an intercalation reaction. J Mol Biol. 39:461–477. 1969. View Article : Google Scholar : PubMed/NCBI
13	Faller LD and LaFond RE: Binding properties of oligomeric alpha-chymotrypsin. Biochemistry. 10:1033–1041. 1971. View Article : Google Scholar : PubMed/NCBI
14	Bubel HC and Wolff DA: Proflavine inhibition of vaccinia virus synthesis. J Bacteriol. 89:977–983. 1965.PubMed/NCBI
15	Scholtissek C and Rott R: Binding of proflavine to deoxyribonucleic acid and ribonucleic acid and its biological significance. Nature. 204:39–43. 1964. View Article : Google Scholar : PubMed/NCBI
16	Orgel A and Brenner S: Mutagenesis of bacteriophage T4 by acridines. J Mol Biol. 3:762–768. 1961. View Article : Google Scholar : PubMed/NCBI
17	Lerman LS: Structural consideration in the interaction of DNA and acridines. J Mol Biol. 3:18–30. 1961. View Article : Google Scholar : PubMed/NCBI
18	Simard R: Specific nuclear and nucleolar ultrastructural lesions induced by proflavin and similarly acting antimetabolites in tissue culture. Cancer Res. 26:2316–2328. 1966.PubMed/NCBI
19	Furuya N, Liang XH and Levin B: Autophagy and cancerAutophagy. Klionsky DJ: Landes Bioscience; Georgetown, TX: pp. 244–253. 2004
20	Mathew R, Karp CM, Beaudoin B, Vuong N, Chen G, Chen HY, Bray K, Reddy A, Bhanot G, Gelinas C, et al: Autophagy suppresses tumorigenesis through elimination of p62. Cell. 137:1062–1075. 2009. View Article : Google Scholar : PubMed/NCBI
21	Hassan S, Laryea D, Mahteme H, Felth J, Fryknäs M, Fayad W, Linder S, Rickardson L, Gullbo J, Graf W, et al: Novel activity of acriflavine against colorectal cancer tumor cells. Cancer Sci. 102:2206–2213. 2011. View Article : Google Scholar : PubMed/NCBI
22	Strese S, Fryknäs M, Larsson R and Gullbo J: Effects of hypoxia on human cancer cell line chemosensitivity. BMC Cancer. 13:3312013. View Article : Google Scholar : PubMed/NCBI
23	Wong CC, Zhang H, Gilkes DM, Chen J, Wei H, Chaturvedi P, Hubbi ME and Semenza GL: Inhibitors of hypoxia-inducible factor 1 block breast cancer metastatic niche formation and lung metastasis. J Mol Med (Berl). 90:803–815. 2012. View Article : Google Scholar : PubMed/NCBI
24	Lim MJ, Ahn JY, Han Y, Yu CH, Kim MH, Lee SL, Lim DS and Song JY: Acriflavine enhances radiosensitivity of colon cancer cells through endoplasmic reticulum stress-mediated apoptosis. Int J Biochem Cell Biol. 44:1214–1222. 2012. View Article : Google Scholar : PubMed/NCBI
25	Polglase AL, McLaren WJ, Skinner SA, Kiesslich R, Neurath MF and Delaney PM: A fluorescence confocal endomicroscope for in vivo microscopy of the upper- and the lower-GI tract. Gastrointest Endosc. 62:686–695. 2005. View Article : Google Scholar : PubMed/NCBI
26	Kiesslich R, Goetz M, Vieth M, Galle PR and Neurath MF: Confocal laser endomicroscopy. Gastrointest Endosc Clin N Am. 15:715–731. 2005. View Article : Google Scholar : PubMed/NCBI
27	Keyhani E, Khavari-Nejad S, Keyhani J and Attar F: Acriflavine-mediated apoptosis and necrosis in yeast Candida utilis. Ann NY Acad Sci. 1171:284–291. 2009. View Article : Google Scholar : PubMed/NCBI
28	Simard R, Langelier, Mandeville NM and Royal A: Inhibitors as tools in elucidating the structure and function of the nucleusThe Cell Nucleus. Busch H: 3. Academic Press Inc.; London: pp. 447–487. 1974
29	Mizushima N and Yoshimori T: How to interpret LC3 immunoblotting. Autophagy. 3:542–545. 2007. View Article : Google Scholar : PubMed/NCBI